W.L. Gore loses bid to toss verdict in stent graft patent loss to C.R. Bard

A Delaware federal judge this week dismissed an attempt from W.L. Gore & Associates to clear a jury finding from March which ruled that 1 of its stent patents was invalid in an ongoing patent spat with C.R. Bard (NYSE:BCR), Law360 reports.
U.S. District Judge Leonard Stark denied 3 motions for judgement, including 2 motions arguing that the judge should find the patent not invalid, according to the report.
In March, a Delaware federal jury awarded a win to C.R. Bard in an ongoing spat with W.L. Gore over ultra thin stent graft patents. An 8-man jury ruled that Bard’s patent does not infringe on Gore’s patent, and that Gore’s patent is invalid.
In July 2015, the companies faced a split decision in their 2nd battle over stent graft patents, as Gore appealed a $1 billion loss in another stent graft case to the U.S. Supreme Court.
In that case, which dated back to the 1970s, Bard alleged that Gore infringed a stent graft patent. In the 2nd case, Gore turned the tables and sued Bard in 2011, alleging infringement of a pair of patents by Bard’s Fluency Plus and Flair devices, according to a June 17 ruling by Magistrate Judge Christopher Burke of the U.S. District Court for Delaware.
Bard moved for summary judgment, arguing that 2 of the limitations claimed in the Gore patents, thickness and diameter, are indefinite. Murray Hill, N.J.-based Bard also argued that the Fluency Plus and Flair grafts “do not infringe the asserted claims because they do not mee...

Source: Mass Device - September 21, 2017 Category: Medical Devices Authors: Fink Densford Tags: Legal News Patent Infringement Stents crbard W.L. Gore & Associates Source Type: news